Skip to Main Content

Podcast Archive

HelixTalk #148 - Grit, Determination, and Entrepreneurship: A Pharmacist’s Career Path to Starting an Independent Pharmacy

Date posted: May 24, 2022, 6:00 am

In this episode, we interview Hetal Patel, PharmD and RFUMS COP alumnus, regarding her career path that eventually led her to open Lebanon Family Pharmacy in TN in 2021. We discuss the challenges and opportunities of starting a new independent pharmacy and what the future of independent pharmacy looks like.

HelixTalk #147 - Key Recommendations from the 2022 AHA/ACC/HFSA Heart Failure Guidelines

Date posted: May 3, 2022, 6:00 am

In this episode, we review new updates and key concepts from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. This guideline is newly published (April 2022) and is a full update of the 2013 guidelines and the 2017 focused update for heart failure.

HelixTalk #146 - New Drugs for Bad Bugs: Six Newer Antibiotics for Multidrug Resistant Pathogens

Date posted: April 12, 2022, 6:00 am

In this episode, we discuss six newer antibiotics that target multidrug resistant gram negative bacteria with Dr. Christie Bertram, PharmD, BCIDP. We review common resistance mechanisms, particularly to carbapenems, and highlight the current role in therapy for the following antibiotics: ceftolozane/tazobactam (Zerbaxa®), ceftazidime/avibactam (Avycaz®), meropenem/vaborbactam (Vabomere®), imipenem/cilastatin/relebactam (Recarbrio®), cefiderocol (Fetroja®), and eravacycline (Xerava®).

HelixTalk #145 - Advancing the Profession: Contraceptive Prescribing by Pharmacists in Illinois

Date posted: March 22, 2022, 6:00 am

In this episode, we bring in two guests to discuss the impact of professional advocacy and resulting professional advancements in the state of Illinois. These guests were the front-line agents of advocacy which resulted in pharmacists' ability to prescribe hormonal contraceptives for patients in Illinois (HB 135). We take a deep dive into their efforts to make this change possible, how it will impact patient care, and its implications on possibilities for further advancement of the pharmacy profession all the while highlighting the importance of professional advocacy.

HelixTalk #144 - mRNA Technologies and their Implications in Therapeutics: Q&A with Dr. Martin

Date posted: March 1, 2022, 6:00 am

In this episode, we interview Dr. Danyelle Martin, a Medical Science Liaison (MSL) at Moderna, in order to learn more about the what, how, and future of mRNA-based therapeutics, and what impact it can have on healthcare and healthcare professionals in general.

HelixTalk #143 - The Low Down on Hypothyroidism: The Essentials of What Healthcare Providers Need to Know

Date posted: February 8, 2022, 6:00 am

In this episode, we review the diagnostic criteria and treatment strategy of hypothyroidism including the controversy surrounding brand versus generic levothyroxine and non-levothyroxine thyroid drugs.

HelixTalk #142 - New Gains in Weight Loss Pharmacotherapy

Date posted: January 18, 2022, 6:00 am

In this episode, we will build up on our previous Weight loss Pharmacotherapy Episode, episode #13 to discuss updates in guidelines, prevention of obesity from comorbidity standpoint, and new treatment agents for weight-loss with a particular focus on Contrave (naltrexone/bupropion), Saxenda (liraglutide), and Wegovy (semaglutide).

HelixTalk #141 - What You Need to Know about Hepatorenal Syndrome: New Definitions, Treatments, and Clinical Pearls

Date posted: December 28, 2021, 6:00 am

In this episode, we provide a concise overview of the diagnosis and treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) with a focus on the new HRS-1 definition (now called HRS-AKI), new data with terlipressin, and the AASLD 2021 guidelines.

HelixTalk #140 - The Ultimate Guide to SSRIs: An In-Depth Drug Class Review

Date posted: December 7, 2021, 6:00 am

In this episode, we review the pharmacology, indications, adverse effects, and unique drug characteristics of the most common SSRIs on the market.

HelixTalk Episode #139 - They Did What?! FDA Approval of Aducanumab for Alzheimer’s Disease

Date posted: November 16, 2021, 6:00 am

In this episode, we discuss the recent accelerated approval of the new monoclonal antibody-based treatment agent, aducanumab (Aduhelm), by the FDA. We dive into the drug approval process, the efficacy and safety data, and the behind-the-scenes story of the FDA approval. Furthermore, we will present the controversy behind the approval and what it means for stakeholders.